Medline ® Abstract for Reference 48
of 'Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors'
48
TI
Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases.
AU
Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA
SO
Ann Intern Med. 2000;133(3):192.
BACKGROUND:
An association between use of zidovudine and didanosine and a rare but life-threatening syndrome of hepatic steatosis, lactic acidosis, and myopathy has been reported.
OBJECTIVE:
To describe the syndrome of hepatic steatosis, lactic acidosis, and myopathy in four patients taking stavudine.
DESIGN:
Case series.
SETTING:
A community hospital in Washington, D.C., and National Institutes of Health Clinical Center, Bethesda, Maryland.
PATIENTS:
Two men and two women with HIV-1 infection who were taking stavudine presented with lactic acidosis and elevated levels of aminotransferases. All patients required intensive care.
MEASUREMENTS:
Levels of lactic acid, alanine aminotransferase, aspartate aminotransferase, amylase, and lipase; computed tomography of the abdomen; liver biopsy (two patients); and muscle biopsy (two patients).
RESULTS:
Histologic findings consistent with mitochondrial injury confirmed the diagnosis of hepatic or muscle abnormality.
CONCLUSION:
Because hepatic steatosis may be life-threatening, physicians should consider it as a possible cause of elevated hepatic aminotransferase levels among patients taking stavudine.
AD
Warren Grant Magnuson Clinical Center, National Institute of Allergy and Infectious Diseases Intramural AIDS Program. National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
PMID